Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

HIV Infections Clinical Trial

Official title:

Double-Blind, Randomized, Placebo-Controlled Study of Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived) in ARC Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00002012
• Other study ID #: 069A
• Secondary ID: 90-151ME
• Status: Completed
• Phase: N/A
• First received: November 2, 1999
• Last updated: June 23, 2005

Study information

• Verified date: March 1993
• Source: NIH AIDS Clinical Trials Information Service
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate symptomatic HIV+, AIDS-related complex (ARC) patients.

Description:

The study has been extended to offer 52 weeks of maintenance therapy after the 10 weeks of the placebo controlled period are concluded successfully.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

Concurrent Medication:

Allowed:

• Zidovudine (AZT).

Patients must have:

• Diagnosis of AIDS related complex (ARC).

• Given written informed consent.

• Been receiving a dose of = or < 600 mg/day of zidovudine (AZT) at least 90 days prior to study entry IF they are currently taking AZT.

Prior Medication:

Allowed:

• Zidovudine (AZT) at a dose = or < 600 mg/day at least 90 days prior to study entry.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

• History of AIDS-defining condition or evidence of AIDS dementia.

• Evidence of chronic hepatitis with severe liver dysfunction, or other active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular or psychiatric disorder that would limit the subject's ability to complete the 12 weeks of the study period.

Concurrent Medication:

Excluded:

• Ketoconazole.

• Trimethoprim / sulfamethoxazole (TMP/SMX).

• Experimental medications.

Patients with the following are excluded:

• Absolute CD4 count of < 100 or > 350 cells/mm3.

• Any disease or disorder listed in Patient Exclusion Co-existing Conditions.

• Unlikely or unable to comply with the requirements of the protocol.

• Unwilling or unable to give informed consent.

• Development of antibodies to interferon during prior interferon therapy that occurred > 3 months prior to study entry.

Prior Medication:

Excluded within 45 days of study entry:

• Immunomodulators (e.g., BCG vaccine, isoprinosine).

• Chemotherapy.

• Steroids.

• Excluded within 3 months of study entry:

• Interferon therapy. Active IV drug abuse.

Study Design

Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Interferon alfa-n3

Locations

Country	Name	City	State
United States	Mount Sinai Med Ctr	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Interferon Sciences

Country where clinical trial is conducted

United States, 

References & Publications (1)

Hassett J, Mendelsohn L. Effect of low dose oral interferon alfa-n3 (IFN) in ARC. Int Conf AIDS. 1993 Jun 6-11;9(1):494 (abstract no PO-B28-2151)